Corvus Pharmaceuticals (CRVS) is a public company. Corvus is a unique environment for exceptional individuals who want to learn, contribute to an exceptional team, and make a difference in the lives of people with cancer. At Corvus, we take pride in our collaborative, community-based culture. We understand that the most successful teams are those that learn from each other and co-create in an environment that nurtures open, transparent communication. Founded in 2014. It has 53 employees. IPO 2016.

Transcript

Operator

Good afternoon, everyone. Thank you for standing by. Welcome to the Corvus Pharmaceuticals Second Quarter 2026 Business Update and Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. It is now my pleasure to turn the call over to Zack Kubow of Real Chemistry. Please go ahead, sir.

Zack Kubow — Senior Group Director, Investor Relations

Thank you, operator. Good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals Second Quarter 2026 Business Update and Financial Results Conference Call. On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer, Leiv Lea, Chief Financial Officer, Jeff Arcara, Chief Business Officer, and Ben Jones, Senior Vice President of Pharmaceutical Development. The executive team will open the call with some prepared remarks, followed by a question-and-answer period. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus's annual report, quarterly report on Form 10-Q for the quarter ended June 30, 2026, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. With that, I'd like to turn the call over to Leiv Lea. Leiv?

Leiv Lea — CFO

Thank you, Zack. I will begin with a brief overview of our second quarter 2026 financials. Then turn the call over to Richard for a